Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
24 Janeiro 2024 - 10:30AM
Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a
clinical-stage TechBio company specializing in developing
AI-Immunology™ powered vaccines, announces an expanded commitment
to developing tailored cancer vaccines by targeting a novel
category of AI-identified tumor antigens, named Endogenous
Retroviruses (ERVs).
The new treatment opportunity may broaden the
applicability of cancer vaccines. Through the new vaccine targets,
ERVs, treating patients unresponsive to conventional cancer
immunotherapy may become possible. With the elevated focus on this
groundbreaking therapeutic concept, Evaxion has initiated
preclinical activities with a goal of generating Proof-of-Concept
data by the second half of 2024.
Evaxion’s Chief Scientific Officer, Birgitte
Rønø, expresses optimism, “With our intensified focus on ERV cancer
vaccines, we aim to expedite the development process to deliver
treatment solutions to cancer patients who, until now, have been
deemed unresponsive to immunotherapy. The ERV cancer vaccine
targets represent a promising breakthrough that could significantly
broaden the horizons of cancer vaccine applicability and marks a
significant step forward in our commitment to improving healthcare
through innovative and AI-powered approaches. We are already seeing
significant interest in ERV-based vaccines and look forward to
further underpinning the significant potential by these
Proof-of-Concept data.”
Recent insights into these exciting
opportunities were presented by Evaxion at the last American
Society of Hematology (ASH) Annual Meeting. For further
information, please see our previous press release.
About ERVs
ERVs are remnants of ancient viruses lying
dormant in our genome. ERVs are often overexpressed in cancer but
not in healthy tissue, making them visible to the immune system and
hence promising targets for cancer vaccines. AI-Immunology™ is
crucial in allowing the identification of therapeutically relevant
ERV tumor antigens from genomic patient tumor data.
About AI-Immunology™
AI-Immunology™ is a scalable and adaptable
artificial intelligence technology platform at the forefront of
vaccine discovery for infectious diseases and cancers. By
integrating the collective power of proprietary AI models PIONEER™,
EDEN™, RAVEN™, and ObsERV™, the platform can model the complexity
of the patient's immune system. AI-Immunology™ advanced
computational modeling swiftly and uniquely identifies,
predicts, and designs vaccine candidates, revolutionizing the
landscape of immunotherapy by offering a holistic and personalized
approach to combat fast-evolving pathogens and malignant cells.
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio
company based upon its AI platform, AI-Immunology™. Evaxion's
proprietary and scalable AI prediction models harness the power of
artificial intelligence to decode the human immune system and
develop novel immunotherapies for cancer, bacterial diseases, and
viral infections. Based upon AI-Immunology™, Evaxion has developed
a clinical-stage oncology pipeline of novel personalized vaccines
and a preclinical infectious disease pipeline in bacterial and
viral diseases with high unmet medical needs. Evaxion is committed
to transforming patients' lives by providing innovative and
targeted treatment options. For more information about Evaxion and
its groundbreaking AI-Immunology™ platform and vaccine pipeline,
please visit our website.
Forward-Looking
StatementThis announcement contains forward-looking
statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. The words "target," "believe,"
"expect," "hope," "aim," "intend," "may," "might," "anticipate,"
"contemplate," "continue," "estimate," "plan," "potential,"
"predict," "project," "will," "can have," "likely," "should,"
"would," "could," and other words and terms of similar
meaning identify forward-looking statements. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various factors,
including, but not limited to, risks related to: our financial
condition and need for additional capital; our development work;
cost and success of our product development activities and
preclinical and clinical trials; commercializing any approved
pharmaceutical product developed using our AI platform technology,
including the rate and degree of market acceptance of our product
candidates; our dependence on third parties including for conduct
of clinical testing and product manufacture; our inability to enter
into partnerships; government regulation; protection of our
intellectual property rights; employee matters and managing growth;
our ADSs and ordinary shares, the impact of international
economic, political, legal, compliance, social and business
factors, including inflation, and the effects on our business
from the worldwide ongoing COVID-19 pandemic and the ongoing
conflict in the region
surrounding Ukraine and Russia and the Middle
East; and other uncertainties affecting our business
operations and financial condition. For a further discussion
of these risks, please refer to the risk factors included in our
most recent Annual Report on Form 20-F and other
filings with the U.S. Securities and Exchange Commission
(SEC), which are available
at www.sec.gov. We do not assume any
obligation to update any forward-looking statements except as
required by law.
Contact Information
Evaxion Biotech A/S
Christian Kanstrup
Chief Executive Officer
cka@evaxion-biotech.com
Source: Evaxion Biotech
Evaxion Biotech AS (NASDAQ:EVAX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024